Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1792772 | 0.98 | CES2 (0.48) | CES2CES1IDO1CA3CA6 | |
| SCHEMBL3079891 | 0.84 | CES2 (0.50) | CES2CES1IDO1ALDH1A1MAPT | |
| SCHEMBL15927202 | 0.77 | CES2 (0.47) | CES2CES1CA3CA6CA5A | |
| SCHEMBL84139 | 0.77 | CES2 (0.56) | CES2CES1CA3CA6CA5A | |
| SCHEMBL84165 | 0.76 | CES2 (0.50) | CES2CES1IDO1CA3CA6 | |
| SCHEMBL246382 | 0.76 | CES2 (0.61) | CES2CES1KEAP1ALDH1A1MAPT | |
| SCHEMBL23938466 | 0.73 | CES2 (0.47) | CES2CES1IDO1CA3CA6 | |
| SCHEMBL20560609 | 0.72 | CES2 (0.56) | CES2CES1CA3CA6CA5A | |
| SCHEMBL800956 | 0.72 | CES2 (0.50) | CES2CES1CA3CA6CA5A | |
| SCHEMBL27673772 | 0.72 | CES2 (0.74) | CES2CES1CA3CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023059605-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023059582-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2018-07-10 | — | — | US | disclosed |
| CN-103951633-B | Mitotic kinesin inhibitors and methods of use thereof | 阿雷生物药品公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-9499503-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2016-11-22 | — | — | US | disclosed |
| CN-103626720-B | Mitotic kinesin inhibitors and using method thereof | 阿雷生物药品公司 | 2016-11-16 | — | — | CN | disclosed |
| EP-2220061-B1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2009052288-A1 | SPIRO-CONDENSED 1, 3, 4-THIADIAZOLE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| US-7449486-B2 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | ARRAY BIOPHARMA, INC. | 2008-07-31 | — | — | US | disclosed |
| EP-1879886-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-101083988-A | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1809280-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006119146-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060247178-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182992-A1 | Antiproliferative agents; anticancer agents; antiinflammatry agents; restenosis; graft versus host disease; autoimmune disease; antiarthritic agents | KIF5B, KIF2C, KIFC1 | CES2 3607/4885CES1 2573/4885IDO1 517/4885 |
| US-20180334441-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885IDO1 4275/4885 |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | CES2 4225/4885CES1 2914/4885IDO1 445/4885 |
| US-10017482-B2 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885IDO1 4275/4885 |
| US-20060247178-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | CES2 2505/4885CES1 1921/4885IDO1 4220/4885 |
| US-20170066733-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF18B, KIF18A | CES2 2733/4885CES1 2193/4885IDO1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.